Advanced urine toxicology testing

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Urine toxicology screening testing is an important standard of care in the addiction and pain treatment setting, offering a reproducible, unbiased, and accurate laboratory test to monitor patients and provide objective support for clinical observations. It has been shown that physicians do not have proficiency in the ordering or interpretation of these tests. This article is an attempt to respond to that need. Current antibody-based enzymatic immunoassays (EIAs) used for urine toxicology screening are useful to detect classes of drugs (ex., opiate) but cannot determine which specific drug (ex., morphine) is present. Gas chromatography and mass spectroscopy can determine exactly which drugs are present, allowing prescribed (or illicit) opiates and benzodiazepines to be identified. This article will discuss principles and details of opiate and benzodiazepine EIA and gas chromatography and mass spectroscopy urine toxicology testing. The approach to detecting patients attributing positive opiate EIAs to prescription opiates who are using heroin or other opioids will be reviewed. Cases of controlled prescription drugs that do not produce the expected positive urine tests (ex., oxycodone producing negative opiate screening tests) will be discussed. How to differentiate codeine from heroin and the role of poppy seeds in toxicology will be examined. The case of an anti-depressant drug that produces false-positive benzodiazepine results and antibiotics that cause positive opiate urine toxicology results will be reviewed. Common benzodiazepines (ex., clonazepam and lorazepam) that do not reliably produce positive benzodiazepine EIAs will be discussed. The approach to detection and management of all these types of toxicology cases will be reviewed, and it is hoped that the analyses presented will impart an adequate information base to medical providers and staff members of drug treatment and pain centers, enabling them to order and interpret these tests in the clinic more effectively as an integrated part of whole patient care.

Original languageEnglish (US)
Pages (from-to)436-448
Number of pages13
JournalJournal of Addictive Diseases
Volume29
Issue number4
DOIs
StatePublished - Oct 2010

Fingerprint

Opiate Alkaloids
Toxicology
Urine
Benzodiazepines
Immunoassay
Heroin
Pharmaceutical Preparations
Gas Chromatography
Mass Spectrometry
Substance Abuse Treatment Centers
Papaver
Oxycodone
Clonazepam
Lorazepam
Pain Clinics
Codeine
Prescription Drugs
Medical Staff
Standard of Care
Morphine

Keywords

  • benzodiazepine
  • clonazepam
  • codeine
  • drug screening
  • EIA
  • ELISA
  • EMIT
  • fluoroquinolone
  • Gas chromatography
  • lorazepam
  • mass spectroscopy
  • morphine
  • opiate
  • sertraline
  • urine toxicology

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Advanced urine toxicology testing. / Tenore, Peter L.

In: Journal of Addictive Diseases, Vol. 29, No. 4, 10.2010, p. 436-448.

Research output: Contribution to journalArticle

@article{f5234e3c90544fff9ed58e1de03ccd15,
title = "Advanced urine toxicology testing",
abstract = "Urine toxicology screening testing is an important standard of care in the addiction and pain treatment setting, offering a reproducible, unbiased, and accurate laboratory test to monitor patients and provide objective support for clinical observations. It has been shown that physicians do not have proficiency in the ordering or interpretation of these tests. This article is an attempt to respond to that need. Current antibody-based enzymatic immunoassays (EIAs) used for urine toxicology screening are useful to detect classes of drugs (ex., opiate) but cannot determine which specific drug (ex., morphine) is present. Gas chromatography and mass spectroscopy can determine exactly which drugs are present, allowing prescribed (or illicit) opiates and benzodiazepines to be identified. This article will discuss principles and details of opiate and benzodiazepine EIA and gas chromatography and mass spectroscopy urine toxicology testing. The approach to detecting patients attributing positive opiate EIAs to prescription opiates who are using heroin or other opioids will be reviewed. Cases of controlled prescription drugs that do not produce the expected positive urine tests (ex., oxycodone producing negative opiate screening tests) will be discussed. How to differentiate codeine from heroin and the role of poppy seeds in toxicology will be examined. The case of an anti-depressant drug that produces false-positive benzodiazepine results and antibiotics that cause positive opiate urine toxicology results will be reviewed. Common benzodiazepines (ex., clonazepam and lorazepam) that do not reliably produce positive benzodiazepine EIAs will be discussed. The approach to detection and management of all these types of toxicology cases will be reviewed, and it is hoped that the analyses presented will impart an adequate information base to medical providers and staff members of drug treatment and pain centers, enabling them to order and interpret these tests in the clinic more effectively as an integrated part of whole patient care.",
keywords = "benzodiazepine, clonazepam, codeine, drug screening, EIA, ELISA, EMIT, fluoroquinolone, Gas chromatography, lorazepam, mass spectroscopy, morphine, opiate, sertraline, urine toxicology",
author = "Tenore, {Peter L.}",
year = "2010",
month = "10",
doi = "10.1080/10550887.2010.509277",
language = "English (US)",
volume = "29",
pages = "436--448",
journal = "Journal of Addictive Diseases",
issn = "1055-0887",
publisher = "Routledge",
number = "4",

}

TY - JOUR

T1 - Advanced urine toxicology testing

AU - Tenore, Peter L.

PY - 2010/10

Y1 - 2010/10

N2 - Urine toxicology screening testing is an important standard of care in the addiction and pain treatment setting, offering a reproducible, unbiased, and accurate laboratory test to monitor patients and provide objective support for clinical observations. It has been shown that physicians do not have proficiency in the ordering or interpretation of these tests. This article is an attempt to respond to that need. Current antibody-based enzymatic immunoassays (EIAs) used for urine toxicology screening are useful to detect classes of drugs (ex., opiate) but cannot determine which specific drug (ex., morphine) is present. Gas chromatography and mass spectroscopy can determine exactly which drugs are present, allowing prescribed (or illicit) opiates and benzodiazepines to be identified. This article will discuss principles and details of opiate and benzodiazepine EIA and gas chromatography and mass spectroscopy urine toxicology testing. The approach to detecting patients attributing positive opiate EIAs to prescription opiates who are using heroin or other opioids will be reviewed. Cases of controlled prescription drugs that do not produce the expected positive urine tests (ex., oxycodone producing negative opiate screening tests) will be discussed. How to differentiate codeine from heroin and the role of poppy seeds in toxicology will be examined. The case of an anti-depressant drug that produces false-positive benzodiazepine results and antibiotics that cause positive opiate urine toxicology results will be reviewed. Common benzodiazepines (ex., clonazepam and lorazepam) that do not reliably produce positive benzodiazepine EIAs will be discussed. The approach to detection and management of all these types of toxicology cases will be reviewed, and it is hoped that the analyses presented will impart an adequate information base to medical providers and staff members of drug treatment and pain centers, enabling them to order and interpret these tests in the clinic more effectively as an integrated part of whole patient care.

AB - Urine toxicology screening testing is an important standard of care in the addiction and pain treatment setting, offering a reproducible, unbiased, and accurate laboratory test to monitor patients and provide objective support for clinical observations. It has been shown that physicians do not have proficiency in the ordering or interpretation of these tests. This article is an attempt to respond to that need. Current antibody-based enzymatic immunoassays (EIAs) used for urine toxicology screening are useful to detect classes of drugs (ex., opiate) but cannot determine which specific drug (ex., morphine) is present. Gas chromatography and mass spectroscopy can determine exactly which drugs are present, allowing prescribed (or illicit) opiates and benzodiazepines to be identified. This article will discuss principles and details of opiate and benzodiazepine EIA and gas chromatography and mass spectroscopy urine toxicology testing. The approach to detecting patients attributing positive opiate EIAs to prescription opiates who are using heroin or other opioids will be reviewed. Cases of controlled prescription drugs that do not produce the expected positive urine tests (ex., oxycodone producing negative opiate screening tests) will be discussed. How to differentiate codeine from heroin and the role of poppy seeds in toxicology will be examined. The case of an anti-depressant drug that produces false-positive benzodiazepine results and antibiotics that cause positive opiate urine toxicology results will be reviewed. Common benzodiazepines (ex., clonazepam and lorazepam) that do not reliably produce positive benzodiazepine EIAs will be discussed. The approach to detection and management of all these types of toxicology cases will be reviewed, and it is hoped that the analyses presented will impart an adequate information base to medical providers and staff members of drug treatment and pain centers, enabling them to order and interpret these tests in the clinic more effectively as an integrated part of whole patient care.

KW - benzodiazepine

KW - clonazepam

KW - codeine

KW - drug screening

KW - EIA

KW - ELISA

KW - EMIT

KW - fluoroquinolone

KW - Gas chromatography

KW - lorazepam

KW - mass spectroscopy

KW - morphine

KW - opiate

KW - sertraline

KW - urine toxicology

UR - http://www.scopus.com/inward/record.url?scp=77957923172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957923172&partnerID=8YFLogxK

U2 - 10.1080/10550887.2010.509277

DO - 10.1080/10550887.2010.509277

M3 - Article

VL - 29

SP - 436

EP - 448

JO - Journal of Addictive Diseases

JF - Journal of Addictive Diseases

SN - 1055-0887

IS - 4

ER -